Prostate cancer is often associated with metastases to bone and/or soft tissue.
The progression to metastatic castrate-resistant prostate cancer is a seminal event in disease progression affecting treatment decisions. A multidisciplinary group was convened to review the currently available imaging guidelines for metastatic disease in prostate cancer and found no consensus on eligibility criteria, type of imaging modality, and the frequency of scanning for detecting metastatic disease. The aim of this review was to present the recommendations from the group to identify optimal strategies for early identification of metastases in patients with prostate cancer.
Click HERE to listen to Thomas E. Keane, MD, one of the authors, discuss this review.
Click HERE to listen to Paul Sieber, MD, one of the authors, discuss this review.
Click HERE to read a commentary by Phillip J. Koo, MD, one of the authors of the article.
Crawford ED, Stone NN, Yu EY, Koo PJ, Freedland SJ, Slovin SF, Gomella LG, Berger ER, Keane TE, Sieber P, Shore ND, Petrylak DP.
University of Colorado, Denver-Aurora, CO; Icahn School of Medicine at Mount Sinai, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Colorado School of Medicine, Denver, CO; Durham VA and Duke University, Durham, NC; Memorial Sloan-Kettering Cancer Center, New York, NY; Thomas Jefferson University, Philadelphia, PA; Oncology Consortium, Scottsdale, AZ; Medical University of South Carolina, Charleston, SC; Lancaster Urology, Lancaster, PA; Carolina Urologic Research Center, Myrtle Beach, SC; Yale University Cancer Center, New Haven, CT; Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR) Group, University of Colorado Hospital, University of Colorado at Denver, Aurora, CO.
Reference: Urology. 2014 Jan 8. pii: S0090-4295(13)01371-X.
UroToday.com mCRPC Treatment Section